Self-insured employers (SIEs) currently rely on traditional stop-loss insurance to protect against unexpected high-cost claims, including those for cell and gene therapies. Given that current approvals are in rare diseases, this approach has succeeded so far. However, as more cell and gene therapies treatments are approved in more prevalent patient populations, this status quo approach may not be sustainable for stop-loss vendors or employers.
Share the research